HER2 Expression in Triple-Negative Breast Cancer: Clinicopathologic Features and Response to Neoadjuvant Chemotherapy

被引：0
|
作者：
Morante, Zaida
Otoya, Iris
Valdivieso, Natalia
Calle, Cindy
Fuentes, Hugo
Neciosup, Silvia
Castaneda, Carlos
Vidaurre, Tatiana
Falla, Martin
Colomo, Valeria
Gomez, Henry
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-03-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-03-10
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
    Budhathoki, Pravash
    Shah, Anish
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [2] Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
    Domergue, Camille
    Martin, Elodie
    Lemarie, Camille
    Jezequel, Pascal
    Frenel, Jean-Sebastien
    Augereau, Paule
    Campone, Mario
    Patsouris, Anne
    [J]. CANCERS, 2022, 14 (10)
  • [3] Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Shi, Yue
    Lu, Heng
    Zhang, Yiqi
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (02) : 387 - 395
  • [4] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    [J]. BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [5] Immunohistochemical Features of Triple Negative Breast Cancer in the Neoadjuvant Setting: Predictors Factors of Response and Evolution of HER2 Expression
    Haro Haro, Carolina
    Zuniga Gaitan, Juzzy Tatiana
    Chaachou Charradi, Anas
    Peg, Vicente
    [J]. LABORATORY INVESTIGATION, 2024, 104 (03) : S171 - S172
  • [6] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [7] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer
    Sneha Phadke
    [J]. Current Oncology Reports, 2022, 24 : 1779 - 1789
  • [8] The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Leon-Ferre, Roberto A.
    Hieken, Tina J.
    Boughey, Judy C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 2111 - 2119
  • [9] The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Roberto A. Leon-Ferre
    Tina J. Hieken
    Judy C. Boughey
    [J]. Annals of Surgical Oncology, 2021, 28 : 2111 - 2119
  • [10] Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
    Atallah, Nehal M.
    Haque, Maria
    Quinn, Cecily
    Toss, Michael S.
    Makhlouf, Shorouk
    Ibrahim, Asmaa
    Green, Andrew R.
    Alsaleem, Mansour
    Rutland, Catrin S.
    Allegrucci, Cinzia
    Mongan, Nigel P.
    Rakha, Emad
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 195
12345